About this trial
Addiction is a brain disorder characterized by a broad range of both apparent and subtle cognitive impairments in attention, memory, executive functions, and decision-making. These cognitive problems are clinically significant and may contribute to poor treatment outcomes in people with Substance Use Disorders (SUDs), such as a high risk of dropout, low treatment compliance, and shorter periods of abstinence. Studies on cognitive function in SUDs reveal that chronic use of drugs and alcohol can also negatively affect another crucial component of cognition: awareness, or metacognition. Metacognition is defined as an individual's ability to perceive and understand their cognitive functions and use this understanding to regulate them. One of the key consequences of metacognitive impairments is the lack of insight in people with SUDs, which adversely affects treatment outcomes. Substance users with poor metacognition are more reluctant to initiate or continue treatment and are more likely to deny their cognitive problems. Therefore, improving metacognition may remove or reduce motivational barriers to invest time and effort in the recovery process in general, and in the brain recovery process specifically. Despite the importance of neurocognition and metacognition in the recovery process for substance users, there is a dearth of interventions designed to target these functions.
Eligibility criteria
Qualifiers
current DSM-5 opioid and/or stimulant use disorder
currently on medication treatment for SUD
owning a smartphone with sufficient functionality to download and utilize the NIPA app.
Disqualifiers
current psychosis, mania, or suicidal/homicidal ideation
non-English speaking
Trial design
Treatments tested in this trial
- Installing the Metacognium software app
- Continue treatment as usual
Treatment groups
Locations
1Sponsors and collaborators
Virginia Commonwealth University
Lead sponsor